Parkinson's disease: pathophysiology

[1]  R. Duvoisin.  On heredity, twins, and Parkinson's disease , 1986, Annals of neurology.

[2]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[3]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[4]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[5]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[6]  J. Langston,et al.  Mechanisms underlying neuronal degeneration in Parkinson's disease: An experimental and theoretical treatise , 1989, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Tarone,et al.  Parkinson's disease and Alzheimer's disease: hypersensitivity to X rays in cultured cell lines. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[8]  S. Hodge,et al.  Twin studies and the genetics of Parkinson's disease—a reappraisal , 1990, Movement disorders : official journal of the Movement Disorder Society.

[9]  Y. Agid,et al.  Does ageing aggravate parkinsonian disability? , 1991, Journal of neurology, neurosurgery, and psychiatry.

[10]  W. Gibb,et al.  A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease , 1988, Neurology.

[11]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[12]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[13]  A. Schapira,et al.  Mitochondrial DNA analysis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[14]  W. Gibb,et al.  The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. , 1990, Advances in neurology.

[15]  R. Waring,et al.  S-METHYLATION IN MOTORNEURON DISEASE AND PARKINSON'S DISEASE , 1989, The Lancet.

[16]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[17]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[18]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[19]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[20]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[21]  K. Jellinger,et al.  New developments in the pathology of Parkinson's disease. , 1990, Advances in neurology.

[22]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[23]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[24]  E. Hirsch,et al.  Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson's disease: An in situ hybridization study , 1990, Neuroscience.

[25]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[26]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[27]  A. Dahlström,et al.  Antibodies in the CSF of a Parkinson patient recognizes neurons in rat mesencephalic regions. , 1986, Acta physiologica Scandinavica.

[28]  S. Gilman,et al.  Advances in neurology (2). , 1992, The New England journal of medicine.

[29]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[30]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[31]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[32]  E. Otero,et al.  Parkinson's Disease: A Genetic Study , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[33]  F Lhermitte,et al.  Age‐induced cognitive disturbances in Parkinson's disease , 1990, Neurology.

[34]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[35]  Y. Agid,et al.  Superoxide dismutase and Parkinson's disease , 1990, The Lancet.

[36]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[37]  C. Marsden.  Parkinson's disease , 1940, The Lancet.

[38]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[39]  D. Ben-shachar,et al.  Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. , 1990, Journal of neural transmission. Supplementum.

[40]  F Lhermitte,et al.  Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? , 1987, Neurology.

[41]  H. Heinsen,et al.  Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique , 1989, Neuroscience.

[42]  Y Agid,et al.  Relationship of aging to Parkinson's disease. , 1987, Advances in neurology.